UGN-101 instillations
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Transitional Cell
Conditions
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Trial Timeline
Apr 4, 2017 → Mar 5, 2020
NCT ID
NCT02793128About UGN-101 instillations
UGN-101 instillations is a phase 3 stage product being developed by UroGen Pharma for Carcinoma, Transitional Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT02793128. Target conditions include Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006691 | Phase 3 | Withdrawn |
| NCT02793128 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Transitional Cell